NPR-B Agonist Peptides for Glaucoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current natriuretic peptides, such as ANP, BNP, and CNP, are ineffective for topical application in treating ocular disorders like glaucoma due to their inability to penetrate the cornea, limiting their use as potent intraocular pressure-lowering agents.
Innovation Solution
Development of novel NPR-B agonists with improved bioavailability and chemical stability, specifically designed to activate the type B natriuretic peptide receptor, which can be used in ophthalmic compositions to treat glaucoma and other disorders mediated by natriuretic peptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If traditional natriuretic peptides (ANP, BNP, CNP) are used to lower intraocular pressure, then the therapeutic effect is achieved through receptor activation, but the peptides cannot penetrate the cornea for topical application
Solution Approach 1:
The patent modifies the molecular parameters of natriuretic peptides by creating truncated analogs (e.g., CNP(22-53) instead of full-length CNP), reducing molecular weight and size to enable corneal penetration while preserving NPR-B receptor binding activity and IOP-lowering effects
Solution Approach 2:
The invention extracts and utilizes only the essential functional domain of CNP (amino acids 22-53) that is responsible for NPR-B activation, discarding the N-terminal region that is not required for receptor binding, thereby creating a minimally active peptide with improved penetrability
2Reliability
If full-length natriuretic peptides are used, then high receptor binding affinity is achieved, but poor chemical stability and rapid degradation occur
Solution Approach 1:
The patent extracts the critical functional region (amino acids 22-53) that mediates NPR-B binding, removing the vulnerable N-terminal portion susceptible to degradation, thereby achieving both stability and retained affinity
Solution Approach 2:
The truncated peptide design creates a shorter, more stable molecule that resists enzymatic degradation compared to full-length peptides, effectively extending the functional lifespan of the therapeutic agent in ocular tissues
3Ease of operation
If traditional natriuretic peptides are applied topically, then the treatment approach is simplified, but the peptides are rapidly degraded by peptidases in the eye
Solution Approach 1:
By changing the molecular size parameter through truncation, the peptide becomes less susceptible to peptidase enzymes, thereby extending its duration of action in the ocular environment while maintaining topical applicability
Solution Approach 2:
The invention converts the potential harm of rapid degradation into a benefit by designing a truncated peptide that is inherently more resistant to enzymatic breakdown, transforming a vulnerability into enhanced therapeutic persistence
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel NPR-B agonists effectively lower intraocular pressure and treat glaucoma by activating the type B natriuretic peptide receptor, offering improved bioavailability and stability compared to traditional natriuretic peptides, thus overcoming the limitations of existing treatments.
Implementation Method 1
activate the type B natriuretic peptide receptor
Implementation Method 2
activating the type B natriuretic peptide receptor
Data Source
AI summary
Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.